A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
NCT06855771
This study is recruiting at 9 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the safety and efficacy of Navlimetostat (BMS-986504) monotherapy or in combination with Izalontamab Brengitecan in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion or MTAP loss after progression on prior therapies.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Carcinoma, Non-Small-Cell Lung
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Bristol-Myers Squibb
- Last updated on ClinicalTrials.gov
- September 18, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- Dana-Farber Cancer Institute · Boston, MA
Michigan · 1
- Karmanos Cancer Institute · Detroit, MI
Missouri · 1
- Washington University School of Medicine · St Louis, MO
New York · 1
- Memorial Sloan Kettering Cancer Center · New York, NY
Ohio · 1
- Gabrail Cancer Center · Canton, OH
Oregon · 2
- Oregon Health and Science University · Portland, OR
- Providence Portland Medical Center · Portland, OR
Washington · 1
- Fred Hutchison Cancer Center · Seattle, WA
Wisconsin · 1
- Medical College of Wisconsin · Milwaukee, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.